Open AccessThe experience of domestic antiviral agents, and some of own approaches in the treatment of chronic hepatitis C in adults
Author(s) -
В. А. Борисов,
Boris Ivanovich Sanin,
Svetlana Evgenievna Samsonova,
E. N Arutyunyan,
D. B Golubeva,
О. В. Зотова,
Т А Фомина
Publication year - 2015
Publication title -
èpidemiologiâ i infekcionnye bolezni
Language(s) - English
Resource type - Journals
eISSN - 2411-3026
pISSN - 1560-9529
DOI - 10.17816/eid40844
Subject(s) - amantadine , medicine , interferon , chronic hepatitis , nucleoside analogue , antiviral treatment , drug , nucleoside , population , antiviral therapy , hepatitis c , immunology , pharmacology , virus , biology , biochemistry , environmental health
In the management of 148 adult patients with chronic hepatitis C (CHC) of both sexes without special selection (taken into account only absolute contraindications to its performance) there were used domestic basic antiviral drugs - BAD\ (short-living interferons (IFN) a, interferon inducers and nucleoside analogues) in parallel with additional antiviral drugs (drug glycyrrhizinic acid or amantadine) and maintenance therapy (stimulators of T-cell immunity and means of correction of side effects). Treatment was carried out in the framework of the developed complex of principles and approaches including in part, the formation of the starting average weekly dose of interferon IFN with accounting of the character of interferon status of the patient, a gradual increase in the average weekly dose of interferon IFN during the course of therapy, the delayed use of nucleoside analogs and others. As a result, against the background of a significant reduction in financial expenses and the aggressiveness of treatment the stable positive therapeutic outcome in the general population ofpatients occurred in 92.6%, with 87.2% in patients with genotype (G) 1.